A Former IVF Baby on "Three-Parent IVF"
By Jessica Cussins,
The Huffington Post
| 10. 24. 2013
I have my parents, and biotechnology, to thank for bringing me into this world; I was an IVF baby. Given this intimate connection with technology and test tubes, you might think I'd be a cheerleader for all developments in the field. But a new technique under consideration has broad and troubling implications, not only for hopeful parents-to-be and their potential future children, but for all of humanity.
This new technique, called mitochondrial replacement or "three-parent IVF," would make genetic changes to IVF embryos and thus to every cell of the children born as a result of it. And these changes would be passed down to future generations. Human inheritable genetic modification of this kind is currently prohibited in over 40 countries and by several international agreements due to numerous problems and concerns. But proposals that would break this long-respected international consensus are now under consideration in the United Kingdom and the United States.
The UK has been toying with the idea for some time and may soon change its law to allow clinical trials. Several US researchers also want...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...